We have identified a list of several trending healthtech stocks that appear have recently received buy ratings from top Wall Street analysts and are showing positive investor sentiment, as well as news headlines. With that said, our editors here at healthtechmovers.com, are adding these healthtech companies to our watchlist to see if this momentum continues. Our watchlist includes trending
Summary: Ventyx Biosciences Inc. is a clinical-stage biopharmaceutical company. It focused on advancing new therapies for patients living with inflammatory diseases and autoimmune disorders. The company's clinical stage pipeline includes VTX958, VTX002 and VTX2735. Ventyx Biosciences Inc. is headquartered in Encinitas, California.
- Recent VTYX Stock Price: $36.85
- Yearly Gain for VTYX stock: 78.50%
- Market Cap for VTYX stock: $1.91B
- P/E Ratio for VTYX stock: -25.884
Will VTYX's stock price go up? Is there an accurate VTYX stock forecast available?
TipRanks.com reports that Ventyx Biosciences currently has 7 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $53.71. The target pricing ranges from a high VTYX forecast of $65.00 down to a low forecast of $35.00. Ventyx Biosciences (VTYX)’s last closing stock price was $36.85 which would put the average price target at 45.75% upside.
In addition, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on VTYX stock.
Other analysts covering VTYX include:
- Emily Bodnar of H.C. Wainwright issued a Buy rating with the price target of $ 50 on 3 days ago
- Yasmeen Rahimi of Piper Sandler issued a Buy rating with the price target of $ 50 on 4 days ago
- Jeff Jones of Oppenheimer issued a Buy rating with the price target of $ 65 on 4 days ago
- Michael Yee of Jefferies issued a Buy rating with the price target of $ 60 on 4 days ago
If you are wondering if VTYX is a good stock to buy, here are 3rd party ratings for VTYX stock:
- TipRanks.com: Strong Buy
- TradingView.com: n/a
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Hold, Top 30% (76 out of 251)
What is the sentiment on the street regarding Ventyx Biosciences? (Current ratings compiled by TipRanks.com)
- News Sentiment for VTYX stock: Very Bullish
- Blogger Consensus for VTYX stock: n/a
- Media Buzz for VTYX stock: Very High
- Insider Signal for VTYX stock: Positive
- Investor Sentiment for VTYX stock: Very Positive
- Hedge Fund signal for VTYX stock: Negative
The stock market is extremely volatile, and you need to do your own research on VTYX stock including scouring the social networks like VTYX StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for VTYX stock chart >>
Summary: Altimmune, Inc. is a clinical-stage immunotherapeutics company. It focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease. The company's proprietary platform technologies consist of RespirVec and Densigen. Altimmune Inc., formerly known as Pharmathene Inc., is based in Gaithersburg, United States.
- Recent ALT Stock Price: $13.67
- Yearly Gain for ALT stock: -12.26%
- Market Cap for ALT stock: $705.47M
- P/E Ratio for ALT stock: -6.401
Will ALT's stock price go up? Is there an accurate ALT stock forecast available?
TipRanks.com reports that Altimmune currently has 6 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $31.67. The target pricing ranges from a high ALT forecast of $50.00 down to a low forecast of $25.00. Altimmune (ALT)’s last closing stock price was $13.67 which would put the average price target at 131.68% upside.
In addition, Barchart.com has a buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on ALT stock.
Other analysts covering ALT include:
- Seamus Fernandez of Guggenheim issued a Buy rating with the price target of $ 26 on 1 day ago
- Jonathan Wolleben of JMP Securities issued a Buy rating with the price target of $ 28 on 1 day ago
- Yasmeen Rahimi of Piper Sandler issued a Buy rating with the price target of $ 25 on 2 days ago
- Mayank Mamtani of B.Riley Financial issued a Buy rating with the price target of $ 26 on 2 days ago
If you are wondering if ALT is a good stock to buy, here are 3rd party ratings for ALT stock:
- TipRanks.com: Strong Buy
- TradingView.com: n/a
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: buy
- Zacks.com: Hold, Top 36% (90 out of 251)
What is the sentiment on the street regarding Altimmune? (Current ratings compiled by TipRanks.com)
- News Sentiment for ALT stock: Neutral
- Blogger Consensus for ALT stock: Bullish
- Media Buzz for ALT stock: Very High
- Insider Signal for ALT stock: Positive
- Investor Sentiment for ALT stock: Very Positive
- Hedge Fund signal for ALT stock: Very Positive
The stock market is extremely volatile, and you need to do your own research on ALT stock including scouring the social networks like ALT StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for ALT stock chart >>
Summary: Regeneron is a biotechnology company focused on the discovery, development and commercialization of treatments targeting serious medical conditions. The company's portfolio boasts nine marketed drugs - Eylea, Dupixent, Praluent, Kevzara, Libtayo, Evkeeza, Inmazeb Arcalyst and Zaltrap. The company also developed an antibody cocktail for COVID-19, REGEN-COV. REGEN-COV is a cocktail of two monoclonal antibodies and was designed specifically to block the infectivity of SARS-CoV-2, the virus that causes COVID-19. Regeneron has a collaboration agreement with Roche for the same. While Regeneron has co-developed Eylea with Bayer's HealthCare unit, Praluent was co-developed with Sanofi. Regeneron collaborated with Bayer for the joint development and commercialization of co-formulated combinations of Eylea, rinucumab and nesvacumab for the treatment of ocular diseases or disorders outside the United States.
- Recent REGN Stock Price: $710.3
- Yearly Gain for REGN stock: 8.28%
- Market Cap for REGN stock: $76.94B
- P/E Ratio for REGN stock: 14.088
Will REGN's stock price go up? Is there an accurate REGN stock forecast available?
TipRanks.com reports that Regeneron currently has 19 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $762.76. The target pricing ranges from a high REGN forecast of $925.00 down to a low forecast of $620.00. Regeneron (REGN)’s last closing stock price was $710.3 which would put the average price target at 6.91% upside.
In addition, Barchart.com has a buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on REGN stock.
Other analysts covering REGN include:
- Evan Seigerman of BMO Capital issued a Buy rating with the price target of $ 788 on 2 days ago
- Mohit Bansal of Wells Fargo issued a Buy rating with the price target of $ 800 on 4 days ago
- Christopher Raymond of Piper Sandler issued a Buy rating with the price target of $ 775 on 4 days ago
- Yatin Suneja of Guggenheim issued a Buy rating with the price target of $ 925 on 4 days ago
If you are wondering if REGN is a good stock to buy, here are 3rd party ratings for REGN stock:
- TipRanks.com: Moderate Buy
- TradingView.com: n/a
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: buy
- Zacks.com: Sell, Top 30% (76 out of 251)
What is the sentiment on the street regarding Regeneron? (Current ratings compiled by TipRanks.com)
- News Sentiment for REGN stock: Very Bullish
- Blogger Consensus for REGN stock: Bullish
- Media Buzz for REGN stock: Medium
- Insider Signal for REGN stock: Negative
- Investor Sentiment for REGN stock: Neutral
- Hedge Fund signal for REGN stock: Very Positive
The stock market is extremely volatile, and you need to do your own research on REGN stock including scouring the social networks like REGN StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for REGN stock chart >>
Summary: G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It engaged in developing novel, small-molecule therapies which address significant unmet needs in the treatment of cancer. The company's product pipeline consists of CDK4/6, Trilaciclib (G1T28), G1T38 and G1T48. G1 Therapeutics, Inc. is based in Research Triangle Park, NC.
- Recent GTHX Stock Price: $15.21
- Yearly Gain for GTHX stock: 8.27%
- Market Cap for GTHX stock: $660.44M
- P/E Ratio for GTHX stock: -3.844
Will GTHX's stock price go up? Is there an accurate GTHX stock forecast available?
TipRanks.com reports that G1 Therapeutics currently has 5 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $34.50. The target pricing ranges from a high GTHX forecast of $67.00 down to a low forecast of $14.00. G1 Therapeutics (GTHX)’s last closing stock price was $15.21 which would put the average price target at 126.82% upside.
In addition, Barchart.com has a Strong buy rating and Yahoo! Finance has a Neutral short-term outlook. Remember, securities are volatile, so please do your own research on GTHX stock.
Other analysts covering GTHX include:
- Gil Blum of Needham issued a Buy rating with the price target of $ 32 on 22 hours ago
- Edward White of H.C. Wainwright issued a Buy rating with the price target of $ 67 on 22 hours ago
- Anupam Rama of J.P. Morgan issued a Sell rating with the price target of $ 14 on 1 month ago
If you are wondering if GTHX is a good stock to buy, here are 3rd party ratings for GTHX stock:
- TipRanks.com: Moderate Buy
- TradingView.com: n/a
- Yahoo! Finance: Neutral Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Hold, Top 30% (76 out of 251)
What is the sentiment on the street regarding G1 Therapeutics? (Current ratings compiled by TipRanks.com)
- News Sentiment for GTHX stock: Very Bullish
- Blogger Consensus for GTHX stock: Bullish
- Media Buzz for GTHX stock: Medium
- Insider Signal for GTHX stock: n/a
- Investor Sentiment for GTHX stock: Positive
- Hedge Fund signal for GTHX stock: Neutral
The stock market is extremely volatile, and you need to do your own research on GTHX stock including scouring the social networks like GTHX StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for GTHX stock chart >>
Summary: The Beauty Health Company is a beauty health company. Its flagship brand HydraFacial is a non-invasive and approachable beauty health platform and ecosystem with a powerful community of estheticians, consumers and partners, bridging medical and consumer retail to democratize and personalize skin care solutions for the masses. The Beauty Health Company, formerly known as Vesper Healthcare Acquisition Corp., is based in CHICAGO, Utah.
- Recent SKIN Stock Price: $11.98
- Yearly Gain for SKIN stock: -51.65%
- Market Cap for SKIN stock: $1.90B
- P/E Ratio for SKIN stock: -6.546
Will SKIN's stock price go up? Is there an accurate SKIN stock forecast available?
TipRanks.com reports that Beauty Health currently has 7 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $23.00. The target pricing ranges from a high SKIN forecast of $30.00 down to a low forecast of $20.00. Beauty Health (SKIN)’s last closing stock price was $11.98 which would put the average price target at 91.99% upside.
In addition, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on SKIN stock.
Other analysts covering SKIN include:
- Korinne Wolfmeyer of Piper Sandler issued a Buy rating with the price target of $ 23 on 22 hours ago
- Allen Gong of J.P. Morgan issued a Buy rating with the price target of $ 22 on 1 day ago
- Jonathan Block of Stifel Nicolaus issued a Buy rating with the price target of $ 20 on 3 weeks ago
- Amit Hazan of Goldman Sachs issued a Buy rating with the price target of $ 22 on 1 month ago
If you are wondering if SKIN is a good stock to buy, here are 3rd party ratings for SKIN stock:
- TipRanks.com: Strong Buy
- TradingView.com: n/a
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Hold, Bottom 36% (159 out of 251)
What is the sentiment on the street regarding Beauty Health? (Current ratings compiled by TipRanks.com)
- News Sentiment for SKIN stock: Neutral
- Blogger Consensus for SKIN stock: Bullish
- Media Buzz for SKIN stock: Very Low
- Insider Signal for SKIN stock: n/a
- Investor Sentiment for SKIN stock: Very Negative
- Hedge Fund signal for SKIN stock: Neutral
The stock market is extremely volatile, and you need to do your own research on SKIN stock including scouring the social networks like SKIN StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for SKIN stock chart >>
Summary: Inari Medical, Inc. is a commercial-stage medical device company committed toward developing products to treat and change the lives of patients suffering from venous diseases. Its initial product offering comprises 2 minimally-invasive, novel catheter-based mechanical thrombectomy devices. It built its products purposely on the basis of the specific characteristics of the venous system and the treatment of the two distinct indications of venous thromboembolism or VTE (deep vein thrombosis and pulmonary embolism/ PE). Its FlowTriever product is the first thrombectomy system, which is FDA-cleared, used for the treatment of PE. Its advanced systems & processes to control the key relationships between its sales representatives and treating physicians like cardiologists, radiologists, helps it to quickly iterate products, launch and execute physician education and training programs and scale its sales organization. The company markets and sells its products to hospitals across the U.S.
- Recent NARI Stock Price: $69.6
- Yearly Gain for NARI stock: -8.30%
- Market Cap for NARI stock: $3.94B
- P/E Ratio for NARI stock: -255.102
Will NARI's stock price go up? Is there an accurate NARI stock forecast available?
TipRanks.com reports that Inari Medical currently has 5 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $94.80. The target pricing ranges from a high NARI forecast of $100.00 down to a low forecast of $87.00. Inari Medical (NARI)’s last closing stock price was $69.6 which would put the average price target at 36.21% upside.
In addition, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on NARI stock.
Other analysts covering NARI include:
- Marie Thibault of BTIG issued a Buy rating with the price target of $ 100 on 1 day ago
- Richard Newitter of Truist Financial issued a Hold rating with the price target of $ 87 on 4 days ago
- Cecilia Furlong of Morgan Stanley issued a Buy rating with the price target of $ 93 on 2 months ago
- Adam Maeder of Piper Sandler issued a Buy rating with the price target of $ 100 on 2 months ago
If you are wondering if NARI is a good stock to buy, here are 3rd party ratings for NARI stock:
- TipRanks.com: Strong Buy
- TradingView.com: n/a
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Hold, Bottom 36% (160 out of 251)
What is the sentiment on the street regarding Inari Medical? (Current ratings compiled by TipRanks.com)
- News Sentiment for NARI stock: Very Bullish
- Blogger Consensus for NARI stock: Bullish
- Media Buzz for NARI stock: Low
- Insider Signal for NARI stock: n/a
- Investor Sentiment for NARI stock: Very Positive
- Hedge Fund signal for NARI stock: Very Positive
The stock market is extremely volatile, and you need to do your own research on NARI stock including scouring the social networks like NARI StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for NARI stock chart >>
One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star Ranking TM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
The Editor, HealthTechMovers.com
HealthTechMovers.com (HTM) is built for investors who are interested in healthcare stocks, health insurance stocks, healthcare technology stocks, biotechnology stocks, pharmaceutical stocks, healthcare service provider stocks, life science stocks and more. HTM aggregates market data from top tier financial content providers like Barchart.com, Tipranks.com, TradingView.com, Yahoo! Finance, and Zacks.com. The research and editorial team behind HTM consolidates this aggregated data into easily consumable reports used to produce articles, newsletters, and web content. The reports produced by HTM contain timely information stock analysis, stock price targets, earnings announcements, insider trades, dividends, and top moving stocks.
Disclaimer: Sandpiper Marketing Group, LLC would like to remind you the data contained in this website is not necessarily real-time nor accurate. All stocks, indexes, futures and Forex prices are not provided by exchanges but rather by our editor research at the time of writing this release, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Sandpiper Marketing does not bear any responsibility for any trading losses you might incur as a result of using this data. Sandpiper Marketing Group, LLC or anyone involved with Sandpiper Marketing Group, LLC will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this website/newsletter is not trustworthy unless verified by their own research. Also, because events/circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
==============================================================================